Gleevec® (imatinib mesylate) Advancing the Treatment of Ph+ Chronic Myeloid Leukemia (CML) Doug Brutlag Professor Emeritus of Biochemistry and Medicine.

Slides:

Advertisements

Similar presentations

Imatinib Resistance Geoffrey L. Uy, M.D. Associate Professor of Medicine Division of Oncology.

Advertisements

The National CML Society 2012 CML UPDATE “What’s New? What’s Coming?” Luke Akard MD Co-Director Indiana Blood and Marrow Transplantation Program.

Integrative Organs Systems Scientists and Drug Discovery: The Link Between Big Pharma and Academia Glenn A. Reinhart, Ph.D. Senior Group Leader Integrative.

Long Term Follow-Up After Imatinib Cessation for Patients in Deep Molecular Response: The Update Results of the STIM1 Study1 Preliminary Report of the.

I’ve just been diagnosed with CML. Could you answer my questions?

Final Study Results of the Phase III Dasatinib versus Imatinib in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Trial (DASISION, CA )1.

This lecture was conducted during the Nephrology Unit Grand Ground by Nephrology Registrar under Nephrology Division, Department of Medicine in King Saud.

Doug Brutlag 2011 Genomics, Bioinformatics & Medicine Drug Development

Anticancer Therapy: Kinase Inhibitors Charles Harrell.

Rakesh Biswas MD Professor, Medicine, People's College of Medical Sciences, Bhopal, India Lecture first conceived and delivered to medicine undergrads.

Marty O’Neill II Carmen Banea

Monitoring CML Treatment: Addressing the Issues for the Community Hematologist/Oncologist Hagop M. Kantarjian, MD Chairman; Professor, Department of Leukemia.

Products of haematopoiesis. Leukaemia, the current hypothesis Defect in maturation of white blood cells-may involve a block in differentiation and/or.

Comparison of Nilotinib and Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTnd Beyond One Year Larson.

Ponatinib as Initial Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Cortes JE et al. Proc ASH 2013;Abstract 1483.

CS 790 – Bioinformatics Introduction and overview.

What are the risks and benefits of Tyrosine Kinase Inhibitors ? Wendy Osborne Consultant Haematologist Freeman Hospital, Newcastle.

Here are some CML slides that may be helpful for your presentation.

Which has the Human Genome Project most improved in the field of medicine? A. the ability to generate vaccines B. the diagnosis and treatment of disease.

Pharmacology Science that studies interactions of drugs with organism on different levels (subcellular, cellular, organ, systemic) Studies: -relationship.

Dose Interruption/Reduction of Tyrosine Kinase Inhibitors in the First 3 Months of Treatment of CML Is Associated with Inferior Early Molecular Responses.

Interesting Developments. Historic trends in biotech fields.

Case Study MICR Hematology Spring, 2011 Case # 5 Hee Jin Kim, Hooman Nikizad and Arthur Omuro.

Current use of imatinib in the treatment of chronic myeloid leukaemia Michael O’Dwyer Haematologica March 2003.

Chapter 1 What is Biochemistry and How Does it Relate to Other Areas

ENESTnd 24-Month Update: Continued Superiority of Nilotinib versus Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.

An Ongoing Phase 3 Study of Bosutinib (SKI-606) versus Imatinib in Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Gambacorti-Passerini.

Epic: A Phase 3 Trial of Ponatinib Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CP-CML) Lipton JH.

Gleevec vs. BMS Druker vs. Sawyers

Questions to the Committee. Question 1. The Agency has accepted durable responses in hematologic malignancies for approval for both chronic leukemias.

Early Molecular and Cytogenic Response Is Predictive for Long-Term Progression-Free and Overall Survival in Chronic Myeloid Leukemia (CML) Hanfstein B.

Treatment of CML. Goal of Therapy Complete molecular remission and cure – Achieve prolonged, durable, nonneoplastic, nonclonal hematopoiesis, – Eradication.

Phase II Study of Dasatinib (BMS ) in Advanced Sarcomas and Chordoma Coordinating Center: U Michigan.

Molecular Monitoring in CML the process and questions we can answer Letizia Foroni.

Dasatinib Compared to Imatinib in Patients with Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase (CML-CP): Twelve- Month Efficacy and Safety.

Chronic myelogenous leukemia Uncommon disease Highly lethal when ineffectively Rxd Most pts are in their 50s+60s The molecular understanding of this disease.

Switching to Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase with Suboptimal Cytogenetic Response on Imatinib: Results from the LASOR.

Bosutinib as Therapy for Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib: 36-Month Minimum Follow-Up Update Cortes.

Case report Sudden blastic transformation in patient with chronic myeloid leukemia treated with imatinib mesylate Mehrdad Payandeh,MD Hematology, Medical.

PHL 616 Drug Discovery & Development Fifth Lecture By Abdelkader Ashour, Ph.D. Phone:

Kantarjian HM et al. Proc ASH 2012;Abstract Long-Term Follow-Up of Ongoing Patients in 2 Studies of Omacetaxine Mepesuccinate for Chronic Myeloid.

Resistance to Targeted Therapy in Chronic Myelogenous Leukemia Andreas Hochhaus, Philipp Erben, Thomas Ernst, and Martin C. Mueller Seminars in Hematology.

Phase III EURO-SKI: Cessation of TKI Therapy Safe, Feasible for Pts Who Achieve Deep Molecular Response New Findings in Hematology: Independent Conference.

Shah N et al. Proc ASH 2010;Abstract 206.

Soverini S et al. Proc ASH 2015;Abstract 346.

Raafat R. Abdel-Malek, MD, FRCR Ass. Prof Clinical Oncology

Early Molecular and Cytogenetic Response Predict for Better Outcomes in Untreated Patients with CML-CP — Comparison of 4 TKI Modalities (Standard- and.

Martinelli G et al. Proc ASH 2015;Abstract 679.

Cortes JE et al. Proc ASCO 2010;Abstract 6502.

Resistant CML: Understanding the Science to Change Outcomes

Monitoring Milestones in Patients With Chronic Myeloid Leukemia

5 Pharmacodynamics.

Chronic Leukemia Kristine Krafts, M.D..

Figure 1 Key time points in the discovery and development of imatinib for the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal.

Best Practices in Chronic Myeloid Leukemia by Multidisciplinary Teams

Luis A. Carvajal, Ulrich Steidl Cell Stem Cell

Mutational Testing to Select Novel Targeted Therapies in AML

Mak Shu Ting (18) Yip Pui Yue (29)

Chronic Myeloid Leukemia Challenge

Crossover for pts meeting ELN 2013 failure criteria

By Amany Helmy Hasanin Assistant Professor of Clinical Pharmacology

Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia.

Pradnya Chopade, Luke P. Akard Clinical Lymphoma, Myeloma and Leukemia

Molecular Monitoring of Chronic Myeloid Leukemia

1Kantarjian HM et al. Lancet Oncol 2011;12:

Leber B et al. Proc ASH 2013;Abstract 94.

Suboptimal Response to or Failure of Imatinib Treatment for Chronic Myeloid Leukemia: What Is the Optimal Strategy? Elias Jabbour, MD, Jorge E. Cortes,

Chronic Myeloid Leukemia: MD-2025 Chisinau, Republic of Moldova

Attacking Cancer at Its Root

Presentation transcript:

Gleevec® (imatinib mesylate) Advancing the Treatment of Ph+ Chronic Myeloid Leukemia (CML) Doug Brutlag Professor Emeritus of Biochemistry and Medicine

CML: a Progressive and Fatal Disease

CML: Linked to a Single Molecular Abnormality

Gleevec® Targets the Cause of CML

Inhibition of Cellular Proliferation by Gleevec

CML: Its Cause and Management

Gleevec®: Pharmacokinetics

Phase I Study: Gleevec® Achieves Hematologic and Cytogenetic Responses

Phase II Results: Highest Response Rates in Chronic Phase

Higher Dose: Longer Time to Disease Progression

IRIS Study: Reevaluating First-Line CML Therapy

IRIS: The Largest Phase III CML Study to Date

Longer Time to Progression With Gleevec®

Higher Cytogenetic Response Rates With Gleevec®

Early Responses in More Patients With Gleevec®

More Patients Remain on Gleevec® Therapy

Most Non-Hematologic Adverse Events Less Common With Gleevec®

Fewer Hematologic Adverse Events With Gleevec®

Massive Protein Kinase Database Abbott Labs Publishes Massive Protein Kinase Dataset, New Statistical Method to Analyze Kinome March 11, 2011 By Adam Bonislawski Scientists from Abbott Laboratories' pharmaceutical-discovery division have released kinomics screening data about how 3,800 different inhibitors affect 172 protein kinases. In a study published last month in the online edition of Nature Chemical Biology, the researchers showed how they tried to group these kinases based on both sequence and pharmacological relationships and by their interactions with various inhibitor chemoty

Gleevec®—CML Indications

Gleevec®—Important Considerations

Gleevec®: Evolving First-Line CML Therapy

NCCN CML Guidelines for Monitoring Response to Gleevec®

Optimal Dosing for Optimal Results

Gleevec® Has Advanced the Treatment of Ph+ CML